scholarly journals Current status, complications and prospects of fecal microbiota transplantation therapy

2021 ◽  
Vol 5 (1) ◽  
pp. 004-009
Author(s):  
Ohara Tadashi
Keyword(s):  
Fecal Microbiota Transplantation ◽  
Gastrointestinal Diseases ◽  
The United States ◽  
Fecal Microbiota ◽  
Current Status ◽  
Recurrent Clostridium Difficile Infection ◽  
Inflammatory Bowel ◽  
Irritable Bowel ◽  
Highly Virulent ◽  
Transplantation Therapy

Currently, the emergence of highly virulent mutants in Europe and the United States has caused refractory recurrent Clostridium difficile infection (RCDI) to be a problem in clinical practice. In 2013, the Netherland group demonstrated breakthrough therapeutic efficacy in fecal microbial transplant (FMT) treatment clinical trials for RCDI, and FMT treatment is rapidly gaining attention. In addition to RCDI, FMT treatment has been attempted in various gastrointestinal diseases such as inflammatory bowel disease, irritable bowel syndrome and chronic constipation, as well as extragastrointestinal diseases. In this review, I would like to describe the current status, complications and prospects of FMT treatment.

Irritable bowel syndrome and transplantation of fecal microbiota. Review

2021 ◽  
Author(s):  
G. D. Fadieienko ◽  
O. Y. Gridnyev
Keyword(s):  
Irritable Bowel Syndrome ◽  
Fecal Microbiota Transplantation ◽  
Positive Outcome ◽  
Fecal Microbiota ◽  
Cochrane Library ◽  
Placebo Control ◽  
Global Improvement ◽  
Recurrent Clostridium Difficile Infection ◽  
Significant Difference ◽  
Irritable Bowel

Objective — to perform analysis of the literature data as regards the efficacy of the use of fecal microbiota transplantation (FMT) in patients with the irritable bowel syndrome (IBS). Materials and methods. The systematic review of the literature (PubMed, MEDLINE, Cochrane Library) has been performed to assess the results of investigation on the use of FMT in adult IBS patients. Results. Currently, FMT is a safe and highly successful method of treatment for recurrent Clostridium difficile infection, and possibility to use FMT in the treatment of other diseases is under investigation. The results of FMT treatment of patients with IBS are contradictory. A number of authors outline fairly high FMT efficacy when used for the treatment of patients with IBS, refractory to the standard methods: it varies from 36 % to 70 % with a duration of adequate symptoms’ relief up to 1 year. However, other authors indicate that the positive FMT clinical effect lasted from 8 weeks to 3 months, after which there was a gradual recovery of symptoms. At the same time, the researchers noted that mostly often the positive outcome was reached after FMT from donors with a higher number of streptococci in the feces. Still others point out that there was no sustained, at least 50‑point reduction in the severity of IBS symptoms from baseline. Some authors did not reveal the advantages of FMT over placebo control and even reported about the higher placebo efficacy. After data generalization no significant difference was revealed in the global improvement in IBS symptoms in patients receiving donor FM versus placebo. However, the attention is drawn to the relationship between the results of FMT with methodology. Indeed, several studies have shown that placebo capsules were more effective than capsules containing donor feces, whereas FMT from donor stool delivered by colonoscopy was superior to FMF from autologous stool. This may be due to the excipients, containing in the capsulated FMT. A number of researchers also indicated that the use of a super donor is necessary for successful FMT and that the response to FMT is dose dependent. Conclusions. To resolve the issue of the expediency of using FMT in routine clinical practice in patients with IBS, more qualitative controlled studies, involving large cohorts of IBS patients and long‑term follow‑up, are required.  

Principles of DNA-Based Gut Microbiota Assessment and Therapeutic Efficacy of Fecal Microbiota Transplantation in Gastrointestinal Diseases

2016 ◽  
Vol 34 (3) ◽  
pp. 279-285 ◽  
Author(s):  
Giovanni Cammarota ◽  
Silvia Pecere ◽  
Gianluca Ianiro ◽  
Luca Masucci ◽  
Diego Currò
Keyword(s):  
Gut Microbiota ◽  
High Throughput Sequencing ◽  
Fecal Microbiota Transplantation ◽  
Gastrointestinal Diseases ◽  
Fecal Microbiota ◽  
Causative Role ◽  
Gastrointestinal Microbiota ◽  
Treatment Protocols ◽  
Irritable Bowel ◽  
Cure Rates

Fecal microbiota transplantation (FMT), a process by which the normal gastrointestinal microbiota is restored, has demonstrated extraordinary cure rates for Clostridium difficile infection and low recurrence. The community of microorganisms within the human gut (or microbiota) is critical to health status and functions; therefore, together with the rise of FMT, the gastrointestinal microbiota has emerged as a ‘virtual' organ with a level of complexity comparable to that of any other organ system and capable to compete with powerful known antibiotics for the treatment of several disorders. Although treatment protocols, donor selection, stool preparation and delivery methods varied widely, with a few reports following an identical protocol, FMT has diffused to other areas where the alterations of the gut microbiota ecology (or dysbiosis) have been theorized to play a causative role, including inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), among several other extra-intestinal disorders (i.e. metabolic syndrome and obesity, multiple sclerosis, cardiovascular diseases). FMT can be relatively simple to perform, but a number of challenges need to be overcome before this procedure is widely accepted in clinical practice, and currently, there is no consensus between the various gastrointestinal organizations and societies regarding the FMT procedure. In this article, we describe the modern high-throughput sequencing techniques to characterize the composition of gut microbiota and the potential for therapeutics by manipulating microbiota with FMT in several gastrointestinal disorders (C. difficile-associated diarrhea, IBD and IBS), with a look on the potential future directions of FMT.

A detailed review on Fecal Microbiota Transplantation (FMT)

2020 ◽  
Vol 10 (1) ◽  
pp. 1-13
Author(s):  
Ananda Deepak V ◽  
Dwarakesh B ◽  
Asifa Nikhat M ◽  
Sridhar SK ◽  
Brito Raj S
Keyword(s):  
Fecal Microbiota Transplantation ◽  
Health Benefit ◽  
Fecal Microbiota ◽  
Autism Spectrum ◽  
Fecal Matter ◽  
Therapeutic Impact ◽  
Recurrent Clostridium Difficile Infection ◽  
Research Scholar ◽  
Disease Condition ◽  
Irritable Bowel

In this developing scientific and medical world there is a keen curiosity in studying the activity of human gut micro flora in the emerging revolutionary medical process, fecal microbiota transplantation. This process is about the incorporation of prepared fecal matter solution from the donor into the recipient’s gut which is mainly done to restore and alter the microbial content in the gut of the recipient and to attain a therapeutic impact with greater health benefit. FMT, a bacteriotherapy has proved itself by successfully treating the recurrent clostridium difficile infection in the patient whose disease condition can’t be improved by antibiotic regimen. It also exhibits its therapeutic impact in disease conditions like obesity, irritable bowel syndrome (IBS), metabolic syndrome, inflammatory bowel disease (IBD). In recent studies, research scholar implemented this Microbiota transfer therapy (MTT) in patient with Autism spectrum disorders (ASD) and attained the greater health benefits.

scholarly journals Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders?

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Youlian Zhou ◽  
Haoming Xu ◽  
Hongli Huang ◽  
Yingfei Li ◽  
Huiting Chen ◽  
...  
Keyword(s):  
Fecal Microbiota Transplantation ◽  
Therapeutic Option ◽  
Fecal Microbiota ◽  
Microbial Dysbiosis ◽  
Therapeutic Value ◽  
Effective Therapeutic Option ◽  
Potential Applications ◽  
Fecal Bacteriotherapy ◽  
Inflammatory Bowel ◽  
Irritable Bowel

Intestinal microbial dysbiosis is associated with various intestinal and extraintestinal disorders. Fecal microbiota transplantation (FMT), a type of fecal bacteriotherapy, is considered an effective therapeutic option for recurrent Clostridium difficile infection (rCDI) and also has important value in other intestinal diseases including irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). The purpose of this review is to discuss promising therapeutic value in extraintestinal diseases associated with gut microbial dysbiosis, including liver, metabolic, chronic kidney, neuropsychiatric, allergic, autoimmune, and hematological diseases as well as tumors.

Sign in / Sign up

Export Citation Format

Share Document